This illustrates ACTL’s potential to remodel the tumor immune milieu and overcome osimertinib resistance of undefined etiology, in contrast to immune-checkpoint inhibitors, which show limited activity in EGFR-mutant advanced NSCLC but confer clear benefit in EGFR-wild-type metastatic disease[108]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.